Jason O’Byrne

Jason O’Byrne was appointed as Chief Financial Officer in February of 2021. An accomplished executive with more than 20 years of experience within high-growth biotechnology environments, Mr. O’Byrne most recently served as Senior Vice President of Finance at Audentes Therapeutics.

As Senior Vice President of Finance at Audentes Therapeutics, Mr. O’Byrne led financial operations of the gene therapy company, including strategic financial planning, SEC reporting, treasury, tax and procurement. Mr. O’Byrne oversaw the financial due diligence and integration related to the company’s acquisition by Astellas Pharma in 2020. Prior to Audentes, Mr. O’Byrne spent 13 years at Genentech/Roche, most recently serving as APAC Regional CFO based in Singapore. Earlier at Genentech, he held finance executive and leadership roles across product development, research, supply chain, and manufacturing in the United States and Switzerland.

Mr. O’Byrne holds a Bachelor of Applied Science in Mechanical Engineering from the University of British Columbia and an MBA in Finance from New York University.